An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy

Shichao Ai, [a] Shuang Zhen, [c] Zhijian Liu, [a] Feng Sun, [a] Xingchen He, [b] Feng Chu, [b] Wenxian Guan * [a] and Jianquan Wang* [b]

[a] Department of General Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, China.

[b] Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, Jiangsu Province 210093, China.

[c] Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China

*corresponding: medguanwx@163.com; wangjianquan006@163.com

A:

B:

iRGD-Heparin

Fig. S1: A: The NMR of H-Su: 4.97-5.33ppm (heparin), 3.54-4.26 ppm (heparin) and 2.27-2.59ppm (-CH2CH2-COOH, H-Su); B: The NMR of iRGD-HP: 5.06-5.34 ppm (heparin), 3.56-4.23 ppm (heparin), 2.42-2.81 ppm (-CH2CH2-CONH-, iRGD-HP), 2.81ppm (iRGD), 1.09 ppm (iRGD).

	PBS	UFH	iHP	Reference Ranges
PT	12.3s	13.0s	12.2s	9-13s
APTT	31.2s	57.3s	36.7s	20-40s
TT	16.0s	*****	33.6s	14-21s

Table. S1: Anticoagulant function evaluation of PBS, iHP and UFH. ("*****" means exceeding the reference range greatly)